Trials / Unknown
UnknownNCT04797910
Effect of Antiviral Therapy on HVPG in Patients With Viral Cirrhosis
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 24 (estimated)
- Sponsor
- Nanfang Hospital, Southern Medical University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Complications associated with portal hypertension are the leading cause of death in patients with cirrhosis. Until now, hepatic venous pressure gradient (HVPG) - the difference between the wedged hepatic venous pressure (WHVP) and the free hepatic vein pressure (FHVP)- has been the criterion standard to determine portal pressure. Antiviral therapy may decrease HVPG which needs to be verified.
Conditions
Timeline
- Start date
- 2021-03-10
- Primary completion
- 2021-12-31
- Completion
- 2022-12-31
- First posted
- 2021-03-15
- Last updated
- 2021-03-15
Source: ClinicalTrials.gov record NCT04797910. Inclusion in this directory is not an endorsement.